InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,365.31
(
0.23%
)
US TECH 100
18,571.18
(
0.20%
)
Dow Jones
38,930.50
(
0.11%
)
Brent Oil
79.67
(
-0.27%
)
Bitcoin
70,670.51
(
-0.13%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Fern Wood

Send PM Follow Ignore
Followers 8
Posts 600
Boards Moderated 0
Alias Born 03/21/2011

Fern Wood

Re: None

Monday, 03/03/2014 11:18:56 AM

Monday, March 03, 2014 11:18:56 AM

Post# of 92948
Perhaps GSK is aware of what ACTC has in way of a treatment for Lupus.
"GSK has called it quits on its GSK2586184 treatment for lupus - which it's developing with Belgian biotech Galapagos (GLPGF) - after a Phase 2 study failed to demonstrate a positive effect."

From Seeking Alpha.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up